Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 14/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.51 |
| ▸ | PGR | P06401 | 1/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | CASP6 | P55212 | 1/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.48 |
| ▸ | CACNG2 | Q9Y698 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11194801 | 0.88 | SLC6A4 (0.64) | GAAKMT2ASLC6A4NR3C1PGR | |
| SCHEMBL9824736 | 0.84 | MAPT (0.57) | GAAKMT2ASLC6A4NR3C1PGR | |
| SCHEMBL10675409 | 0.83 | NR3C1 (0.59) | GAAKMT2ASLC6A4NR3C1PGR | |
| SCHEMBL10682617 | 0.81 | GAA (0.62) | GAAKMT2ASLC6A4NR3C1PGR | |
| SCHEMBL9096425 | 0.81 | GAA (0.55) | GAAKMT2APDE3BPDE3A | |
| SCHEMBL2718633 | 0.80 | GAA (0.67) | GAAKMT2ASLC6A4NR3C1PGR | |
| SCHEMBL9098720 | 0.80 | GAA (0.57) | GAAKMT2APDE3BPDE3A | |
| SCHEMBL7267767 | 0.79 | SLC6A4 (0.72) | GAAKMT2ASLC6A4NR3C1PGR | |
| SCHEMBL9824743 | 0.79 | MAPKAPK2 (0.53) | GAAKMT2A | |
| SCHEMBL9824612 | 0.78 | PDE3B (0.83) | GAAKMT2ASLC6A4NR3C1PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | C4 THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11787802-B2 | Dihydrobenzimidazolones for medical treatment | CRBN, CUL4A, ADRM1 | GAA 1982/4885KMT2A 1817/4885SLC6A4 3729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.